+44 (0) 1223 755950
+1 832 327 7413
V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB) Antibody
REQUEST MORE INFO
Catalogue No: abx011457
Price:
US$406.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB) Antibody is a Rabbit Polyclonal antibody for the detection of RELB. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo-or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.
Research Articles on V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB)
| Target | V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB) |
| Clonality | Polyclonal |
| Reactivity | Human |
| Tested Applications | ELISA, WB |
| Host | Rabbit |
| Recommended dilutions | WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Immunogen | v-rel reticuloendotheliosis viral oncogene homolog B |
| Isotype | IgG |
| Form | Liquid |
| Purity | ≥ 95% (SDS-PAGE) |
| Purification | Purified by immunogen affinity chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Validity | 12 months. |
| UniProt Primary AC | Q01201 (UniProt, ExPASy) |
| UniProt Secondary AC | Q6GTX7, Q9UEI7 |
| UniProt Entry Name | RELB_HUMAN |
| Gene Symbol | RELB |
| GeneID | 5971 |
| OMIM | 604758 |
| HGNC | 9956 |
| KEGG | hsa:5971 |
| Ensembl | ENSG00000104856 |
| String | 9606.ENSP00000221452 |
| Molecular Weight | Observed MW: 56 kDa |
| Buffer | PBS, pH 7.3, with 0.02% sodium azide and 50% glycerol. |
| Concentration | 2 mg/ml |
| Availability | Shipped within 5-12 working days. |
| Note | This product is for research use only. |